IRCT201207303799N4 IRCT 2013-05-04 Tehran University of Medical Sciences Vice chancellor for research Oral low dose Amiodarone and prevention of atrial fibrillation The effects of oral low dose amiodarone in prevention of atrial fibrillation after coronary artery bypass graft (A Placebo-Controlled Randomized Clinical Trial) 2012-08-22 anticipated 170 Complete https://irct.ir/trial/3917 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention. 2 Coronary Artery Diseases. Intervention 1: In the intervention group with systolic blood pressure above 80 mmgh and rate of more than 60/min, a total of 4.2 grams oral amiodarone is administered as: 600 mg, the night before surgery and also 600 mg, on the morning of surgery and then from the first day after operation followed by 200 mg every 8 hours for five days after surgery. Amiodarone is an antiarrhythmic drug used for various types of cardiac dysrhythmias, both ventricular and atrial. In this study, the oral form of amiodarone is used. Each tablet contains 200 mg amiodarone hydrochloride. This product is manufactured by Amin pharmaceutical company. Intervention 2: Patients in the control group receive placebo pills which are specifically designed to have no real effect. They are made of an inert substance. These tablets in terms of size, shape, packaging and name are exactly similar to the amiodarone tablets. Only the code written on the boxes are different from each other. Frequency and duration of using placebo pills in the control group are absolutely the same as amiodarone pills in the intervention group. This product is manufactured by Amin pharmaceutical company.